


#### PHARMACEUTICAL 2022

## **Aquestive**

### Aquestive Therapeutics Inc. Rank 380 of 475





#### PHARMACEUTICAL 2022



# Aquestive Therapeutics Inc. Rank 380 of 475

The relative strengths and weaknesses of Aquestive Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aquestive Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 144% points. The greatest weakness of Aquestive Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 241% points.

The company's Economic Capital Ratio, given in the ranking table, is -366%, being 89% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	47,259
Cost of Goods Sold	0
Intangible Assets	51
Liabilities, Current	21,964
Liabilities, Non-Current	11,553
Other Assets	9,628
Other Compr. Net Income	0
Other Expenses	37,450
Other Liabilities	110,610
Other Net Income	-13,822
Property and Equipment	5,055
Research and Development	17,047
Revenues	51,255
Selling, General and Administrative Expense	53,475

Output Variable	Value in 1000 USD
Assets	61,993
Liabilities	144,127
Expenses	107,972
Stockholders Equity	-82,134
Net Income	-70,539
Comprehensive Net Income	-70,539
Economic Capital Ratio	-366%